Advertisement

Science-Business eXchange

, Volume 4, Issue 37, pp 1032–1032 | Cite as

STK33 strikes out

  • Lev Osherovich
Article
  • 131 Downloads

Abstract

Amgen has dropped its STK33 program after company scientists were unable to reproduce academic findings that serine/threonine kinase 33 could be a target for treating tumors driven by K-Ras mutations.

Copyright information

© Nature Publishing Group 2011

Authors and Affiliations

  • Lev Osherovich

There are no affiliations available

Personalised recommendations